The webinar will review the Italfarmaco Givinostat development program for Duchenne and Becker Muscular Dystrophy. Content that will be covered, includes:
Updates from the EPIDYS Study, a phase 3 clinical trial of Givinostat in ambulatory boys with DMD.
Data from Italfarmaco’s long term studies of Givinostat in DMD populations.
30 minute Q & A.
Paolo Bettica, MD, PhD Vice President of Research and Development, Italfarmaco S.p.A
Michael Kelly, Chief Scientific Advisor, CureDuchenne
Ana Christensen, Patient Science Liaison, TRINDS